循環器ジャーナル66巻1号

2018年01月発行

特集 循環器診療　薬のギモン—エキスパートに学ぶ薬物治療のテクニック Ⅳ．不整脈診療でのギモン

心不全の人のAF．β遮断薬はどう考えるの？

著者： 平井雅之¹ 山本一博¹

所属機関： ¹鳥取大学医学部附属病院病態情報内科学

ページ範囲：P.116 - P.121

Point
・心房細動が心不全の基礎疾患になっているのか，それとも心機能障害に関連した合併症とした位置付けなのかを評価する必要がある．
・心房細動を合併した心不全の急性期においては，心不全管理とともにβ遮断薬を中心としたレートコントロールを行う．
・心房細動合併心不全の慢性期におけるβ遮断薬については洞調律患者以上に有効性を評価しながら使用する必要がある．

参考文献

1) Maisel WH, Stevenson LW:Atrial fibrillation in heart failure:epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91:2D-8D, 2003

2) Lubitz SA, Moser C, Sullivan L, et al:Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. J Am Heart Assoc 2:e000126, 2013

3) Healey JS, Oldgren J, Ezekowitz M, et al:Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation:a cohort study. Lancet 388:1161-1169, 2016

4) 三明淳一朗，山本一博：頻脈誘発性心筋症診断の新局面．医学のあゆみ252:1106-1111, 2015

5) 日本循環器学会．循環器病の診断と治療に関するガイドライン：心房細動治療（薬物）ガイドライン（2013年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf

6) Bui AL, Grau-Sepulveda MV, Hernandez AF, et al:Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. Am Heart J 165:567-574, 2013

7) Van Gelder IC, Groenveld HF, Crijns HJ, et al:Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362:1363-1373, 2010

8) Kirchhof P, Benussi S, Kotecha D, et al:2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893-2962, 2016

9) Ponikowski P, Voors AA, Anker SD, et al:2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol（Engl Ed）69:1167, 2016

10) Nagai R, Kinugawa K, Inoue H, et al:Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction:comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin（J-Land Study）. Circ J 77:908-916, 2013

11) Vamos M, Erath JW, Hohnloser SH:Digoxin-associated mortality:a systematic review and meta-analysis of the literature. Eur Heart J 36:1831-1838, 2015

12) Washam JB, Stevens SR, Lokhnygina Y, et al:Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes:a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation（ROCKET AF）. Lancet 385:2363-2370, 2015

13) Ziff OJ, Lane DA, Samra M, et al:Safety and efficacy of digoxin:systematic review and meta-analysis of observational and controlled trial data. BMJ 351:h4451, 2015

14) Kotecha D, Holmes J, Krum H, et al:Efficacy of β blockers in patients with heart failure plus atrial fibrillation:an individual-patient data meta-analysis. Lancet 384:2235-2243, 2014

15) Cadrin-Tourigny J, Shohoudi A, Roy D, et al:Decreased Mortality With Beta-Blocker in Patients With Heart Failure and Coexisting Atrial Fibrillation:An AF-CHF Substudy. JACC Heart Fail 5:99-106, 2017

16) Okamoto H, Hori M, Matsuzaki M, et al:Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol:Japanese chronic heart failure（J-CHF）study. Int J Cardiol 164:238-244, 2013

17) Swedberg K, Komajda M, Böhm M, et al:Ivabradine and outcomes in chronic heart failure（SHIFT）:a randomised placebo-controlled study. Lancet 376:875-885, 2010

18) Ho JE, Lyass A, Lee DS, et al:Predictors of new-onset heart failure:differences in preserved versus reduced ejection fraction. Circ Heart Fail 6:279-286, 2013

19) Zakeri R, Chamberlain AM, Roger VL, et al:Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction:a community-based study. Circulation 128:1085-1093, 2013

20) Yamamoto K, Origasa H, Hori M, et al:Effects of carvedilol on heart failure with preserved ejection fraction:the Japanese Diastolic Heart Failure Study（J-DHF）. Eur J Heart Fail 15:110-118, 2013